• Cisapride (R 51619) in Cardiac Electrophysiology Research

  2026-07-01

  Cisapride (R 51619) is a nonselective 5-HT4 receptor agonist and potent hERG channel inhibitor used to dissect serotonergic signaling and cardiac arrhythmia mechanisms. Its high solubility in DMSO and robust purity enable reproducible in vitro studies. APExBIO provides validated quality control for research reliability.

• Light-Inducible RNA Switches for Precision Gene Therapy Cont

  2026-07-01

  The reference study introduces a rationally designed light-inducible RNA-releasing protein that enables rapid, reversible, and tissue-specific control of mRNA translation in vivo. This approach advances optogenetic gene therapy by allowing temporal regulation of therapeutic transgene expression, with demonstrated benefits in metabolic and retinal disease models.

• Pregnenolone Carbonitrile: Advancing Hepatic and Xenobiotic

  2026-06-30

  Pregnenolone Carbonitrile (PCN) is redefining translational research in xenobiotic metabolism and liver fibrosis. By bridging foundational mechanisms with actionable guidance, this article details how PCN's activation of PXR, cytochrome P450 induction, and antifibrotic actions converge on the gut-liver axis. We synthesize recent evidence on microbiota-mediated hepatoprotection, highlight protocol essentials, and chart strategic pathways for next-generation translational models, establishing PCN as an indispensable, multi-modal research tool.

• Ac-YVAD-CMK: Precision Caspase-1 Inhibition in Pyroptosis Re

  2026-06-30

  Explore Ac-YVAD-CMK as a selective caspase-1 inhibitor for dissecting pyroptosis and inflammatory cytokine release. This article reveals its mechanistic value, protocol nuances, and unique research applications beyond conventional approaches.

• EDC.HCl (3-(ethyliminomethylideneamino)-N,N-dimethylpropan-1

  2026-06-29

  EDC.HCl (3-(ethyliminomethylideneamino)-N,N-dimethylpropan-1-amine hydrochloride) is a water-soluble carbodiimide reagent optimized for amide bond formation in peptide synthesis, bioconjugation, and nucleotide coupling workflows. It should be used exclusively in controlled in vitro protocols, as there is no supporting data for in vivo or clinical use.

• FPH1 (BRD-6125) Elevates Human Hepatocyte Proliferation Assa

  2026-06-29

  FPH1 (BRD-6125) is redefining functional human hepatocyte expansion with robust, donor-independent proliferation and enhanced hepatic function metrics. Its integration into workflows advances both regenerative medicine and gene therapy, especially when paired with optogenetic gene control.

• Trichostatin A for Epigenetic Regulation and Cancer Research

  2026-06-28

  Trichostatin A (TSA) is the benchmark HDAC inhibitor for dissecting epigenetic mechanisms and suppressing breast cancer cell proliferation. This article provides actionable workflows, troubleshooting strategies, and analytical insights for maximizing the impact of TSA in cancer and epigenetic studies.

• Differential SHH Expression Governs Urethral Development in

  2026-06-27

  This study reveals that differences in prepuce and urethral groove formation between guinea pigs and mice are regulated by distinct expression profiles of Shh, Fgf10, and Fgfr2. These findings challenge mouse-centric models and provide new insights for comparative and congenital malformation research in mammalian penile development.

• Cy5-UTP: Advancing Mechanistic RNA Probe Design for Translat

  2026-06-26

  Explore how Cy5-UTP (Cyanine 5-UTP) is redefining fluorescent RNA labeling workflows in translational research. This thought-leadership article bridges mechanistic insight with practical guidance, highlighting its value for in vitro transcription, advanced FISH, and emerging mRNA delivery innovations.

• Oteseconazole (VT-1161): Optimizing Antifungal Workflows

  2026-06-26

  Oteseconazole (VT-1161) sets a new benchmark for antifungal research, offering selective, potent inhibition of Candida—even fluconazole-resistant strains. This guide translates bench research into stepwise protocols, advanced applications, and troubleshooting for maximizing compound performance.

• 2,5-di-tert-butylbenzene-1,4-diol (BHQ) in HSC Mobilization

  2026-06-25

  Harnessing the selective SERCA inhibition of 2,5-di-tert-butylbenzene-1,4-diol (BHQ) enables precise control of intracellular calcium and facilitates advanced hematopoietic stem cell (HSC) mobilization strategies. This guide distills recent reference breakthroughs into actionable protocols, troubleshooting tips, and comparative insights for calcium signaling research.

• Toremifene Citrate: 20 Years of Data in Breast Cancer Therap

  2026-06-25

  This review synthesizes two decades of clinical and translational research on Toremifene Citrate as an oral selective estrogen receptor modulator (SERM) in breast cancer. It critically examines the compound's mechanistic advances, comparative efficacy, and safety profile, offering researchers a nuanced understanding of its role in hormone receptor modulation and personalized cancer therapy.

• hiPSC-Derived Intestinal Organoids Advance PK Modeling with

  2026-06-24

  This study introduces a streamlined protocol to generate human induced pluripotent stem cell (hiPSC)-derived intestinal organoids suitable for pharmacokinetic research. The organoids retain key physiological and metabolic features—including CYP2C19 activity—offering a robust, renewable in vitro platform for evaluating orally administered drugs and their metabolism.

• Imipramine: Bridging Autophagy, Apoptosis, and Translational

  2026-06-23

  This thought-leadership article explores Imipramine’s mechanistic role as a tricyclic antidepressant in modulating autophagy and apoptosis, drawing on cutting-edge lipidomics and virology studies to offer strategic guidance for translational researchers. By contextualizing Imipramine’s emerging use in cancer, neuroscience, and immunology, the article highlights experimental protocols, cross-domain insights, and research outlooks, while distinguishing itself from standard product pages with in-depth evidence synthesis and actionable strategies.

• Cabozantinib (XL184): Multi-Kinase Inhibition in Cancer Mode

  2026-06-23

  Cabozantinib (XL184) is a potent inhibitor of multiple receptor tyrosine kinases central to tumor progression and angiogenesis. It demonstrates benchmark efficacy in renal cell carcinoma and medullary thyroid cancer models, validated by both phosphoproteomic and in vivo studies. This dossier details its biochemical selectivity, antiangiogenic benchmarks, and integration into advanced cancer signaling workflows.

15714 records 1/1048 page Next 12345 下5页 Last page